Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation

Abstract

Over 50 years of cancer therapy history reveals complete clinical responses (CRs) from remarkably divergent forms of therapies (eg, chemotherapy, radiotherapy, surgery, vaccines, autologous cell transfers, cytokines, monoclonal antibodies) for advanced solid malignancies occur with an approximately similar frequency of 5%–10%. This has remained frustratingly almost static. However, CRs usually underpin strong durable 5-year patient survival. How can this apparent paradox be explained? Over some 20 years, realization that (1) chronic inflammation is intricately associated with cancer, and (2) the immune system is delicately balanced between responsiveness and tolerance of cancer, provides a greatly significant insight into ways cancer might be more effectively treated. In this review, divergent aspects from the largely segmented literature and recent conferences are drawn together to provide observations revealing some emerging reasoning, in terms of “final common pathways” of cancer cell damage, immune stimulation, and auto-vaccination events, ultimately leading to cancer cell destruction. Created from this is a unifying overarching concept to explain why multiple approaches to cancer therapy can provide complete responses at almost equivalent rates. This “missing” aspect provides a reasoned explanation for what has, and is being, increasingly reported in the mainstream literature – that inflammatory and immune responses appear intricately associated with, if not causative of, complete responses induced by divergent forms of cancer therapy. Curiously, whether by chemotherapy, radiation, surgery, or other means, therapy-induced cell injury results, leaving inflammation and immune system stimulation as a final common denominator across all of these mechanisms of cancer therapy. This aspect has been somewhat obscured and has been “lost in translation” to date.

Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit

“…This raises the distinct possibility of systemic immune modulation from “autovaccination” events as a result of tumor necrosis induced by ILI chemotherapy, which has been proposed previously 30. Similar reports have been made for other local therapies associated with direct lesional injection of melanoma metastases, and topical desensitising therapies such as diphencyprone (DPCP), where “bystander”-type regressions have been noted in noninjected metastases 31–34…”

Ethanolic Extract from Derris scandens Benth Mediates Radiosensitzation via Two Distinct Modes of Cell Death in Human Colon Cancer HT-29 Cells

“…Its efficacy depends on the tumor's responsiveness to the fatal effects of radiation (Coventry and Ashdown, 2012). However, several malignancies are relatively radioresistant, leading to treatment failure (Gavriel et al, 2011;Hanson et al, 2012;Mannino and Chalmers, 2011).…”

Cryoablation: physical and molecular basis with putative immunological consequences

“…It is widely recognized that no single monotherapy provides assurance of cure especially with repetitive therapies. Absent a complete clinical response, radiotherapy provides 'curative outcomes' of 5-10% for metastatic malignancies and 60-80% for organ confined disease [21]. Patient outcomes are similar following chemotherapy, hormonal ablation and diverse thermal therapies.…”